Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock
CAN-SHOCK
1 other identifier
observational
303
2 countries
10
Brief Summary
This registry will provide information about the efficacy and safety of cangrelor in a very high-risk group of patients with acute myocardial infarction undergoing PCI. It will not only include patients with cardiogenic shock, but a variety of patients not able to swallow tablets, such as those after CPR and/or with invasive or non-invasive ventilation. Therefore it will provide information about the use of cangrelor beyond the current knowledge.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2021
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 15, 2020
CompletedFirst Posted
Study publicly available on registry
November 2, 2020
CompletedStudy Start
First participant enrolled
May 4, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 7, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 7, 2022
CompletedJuly 27, 2022
March 1, 2022
1.1 years
October 15, 2020
July 26, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Definite stent thrombosis
Rate of stent thromboses
from procedure for index MI up to 48 hours
Recurrent myocardial infarction
Rate of recurrent myocardial infarction according to the universal definition of MI
from procedure for index MI up to 48 hours
Secondary Outcomes (4)
Definite stent thrombosis
from procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days
Recurrent myocardial infarction
from procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days
Bleeding complications
from procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days
Mortality
from procedure for index MI until discharge from hospital; up to 30 days
Eligibility Criteria
Patients with acute myocardial infarction (STEMI, NSTEMI) undergoing PCI and treated with cangrelor after CPR / in cardiogenic shock / with mechanical or non-invasive ventilation
You may qualify if:
- Age ≥18 years
- Acute Myocardial infarction (NSTEMI or STEMI)
- PCI with stent implantation
- Treatment with cangrelor during index procedure
- At least one of the following criteria:
- CPR prior to PCI
- Cardiogenic shock
- Heart failure with the need for mechanical or non-invasive ventila-tion
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (10)
Universitätsklinikum Graz
Graz, Austria
Klinik Ottakring
Vienna, Austria
Fürst-Stirum Klinikum Bruchsal
Bruchsal, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Klinikum Leverkusen
Leverkusen, Germany
Klinikum Ludwigshafen
Ludwigshafen, Germany
Universitätsklinikum Mannheim
Mannheim, Germany
Hegau-Bodensee Klinikum Singen
Singen, Germany
Krankenhaus Maria-Hilf
Stadtlohn, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Study Officials
- PRINCIPAL INVESTIGATOR
Uwe Zeymer, Prof
Klinikum Ludwigshafen ; Stiftung IHF Institut für Herzinfarktforschung
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 15, 2020
First Posted
November 2, 2020
Study Start
May 4, 2021
Primary Completion
June 7, 2022
Study Completion
June 7, 2022
Last Updated
July 27, 2022
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will not share